Publications dans lesquelles il/elle collabore avec Javier Muñiz (26)

2022

  1. A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry

    Expert Opinion on Pharmacotherapy, Vol. 23, Núm. 12, pp. 1457-1465

  2. Impact of Integrated Care Management on Clinical Outcomes in Atrial Fibrillation Patients: A Report From the FANTASIIA Registry

    Frontiers in Cardiovascular Medicine, Vol. 9

2021

  1. Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A report from the FANTASIIA registry

    European Journal of Clinical Investigation, Vol. 51, Núm. 4

  2. Relationship between multimorbidity and outcomes in atrial fibrillation

    Experimental Gerontology, Vol. 153

2020

  1. Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIIA Registry

    Journal of the American Heart Association, Vol. 9, Núm. 1

  2. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a “Real-world” Nationwide Registry: Insights From the FANTASIIA Study

    Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 25, Núm. 4, pp. 316-323

  3. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study

    Revista Espanola de Cardiologia, Vol. 73, Núm. 1, pp. 14-20

  4. INR during stroke and bleeding in patients with atrial fibrillation and on vitamin K antagonists

    REC: CardioClinics, Vol. 55, Núm. 3, pp. 131-138

  5. Influence of sex on long-term prognosis in patients with atrial fibrillation treated with oral anticoagulants. Results from the prospective, nationwide FANTASIIA study

    European Journal of Internal Medicine, Vol. 78, pp. 63-68

  6. La INR durante los ictus y las hemorragias en pacientes con fibrilación auricular tratados con antagonistas de la vitamina K

    REC: CardioClinics, Vol. 55, Núm. 3, pp. 131-138

  7. Prognostic impact of inappropriate doses of direct oral anticoagulants in clinical practice

    Revista Espanola de Cardiologia, Vol. 73, Núm. 4, pp. 329-330

  8. Relationship of adverse events to quality of anticoagulation control in atrial fibrillation patients with diabetes: real-world data from the FANTASIIA Registry

    Annals of Medicine, Vol. 52, Núm. 6, pp. 300-309

2018

  1. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: Prevalence and associated factors. A subanalysis of the FANTASIIA registry

    Europace, Vol. 20, Núm. 10, pp. 1577-1583

  2. Quality of oral anticoagulation with Vitamin K antagonists in 'real-world' patients with atrial fibrillation: A report from the prospective multicentre FANTASIIA registry

    Europace, Vol. 20, Núm. 9, pp. 1435-1441

  3. Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIIA Registry

    Thrombosis and Haemostasis, Vol. 118, Núm. 2, pp. 279-287

  4. Relation of quality of anticoagulation control with different management systems among patients with atrial fibrillation: Data from FANTASIIA Registry

    European Journal of Clinical Investigation, Vol. 48, Núm. 5

2017

  1. Differences in the Characteristics and Management of Patients With Atrial Fibrillation Followed-up by Cardiologists and Other Specialists

    Revista Espanola de Cardiologia, Vol. 70, Núm. 10, pp. 883-886

  2. Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation

    American Journal of Cardiology, Vol. 120, Núm. 12, pp. 2176-2181

2016

  1. Cardiopatía estructural en pacientes anticoagulados con fibrilación auricular no valvular: prevalencia y perfil clínico en una muestra nacional

    Revista Espanola de Cardiologia, Vol. 69, Núm. 10, pp. 986-990

  2. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation

    Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 21, Núm. 2, pp. 150-156